VIATRIS INC. Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax
VIATRIS INC. (VTRS) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax of -$5.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax · last filed 2026-08-06
- VIATRIS INC. other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax for the quarter ending 2026-06-30 was -$5.20M, a 966.67% decline year-over-year.
- VIATRIS INC. other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax for the quarter ending 2026-03-31 was -$3.30M, a 137.93% decline year-over-year.
- VIATRIS INC. other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax for the quarter ending 2025-09-30 was -$2.10M, a 333.33% decline year-over-year.
- VIATRIS INC. other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax for the quarter ending 2025-06-30 was $600.00K, a 92.86% decline year-over-year.
- VIATRIS INC. other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax for fiscal 2022 was $84.70M, a 218.42% increase from fiscal 2021.
- VIATRIS INC. other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax for fiscal 2021 was $26.60M, a 8766.67% increase from fiscal 2020.
- VIATRIS INC. other comprehensive income (loss), cash flow hedge, gain (loss), reclassification, before tax for fiscal 2020 was $300.00K.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax 3 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax 3 month as first filed | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax 6 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax 9 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax 9 month as first filed | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$5.20M 10-Q · filed 2026-08-06 | -$8.50M 10-Q · filed 2026-08-06 | ||||
| 2026-03-31 | -$3.30M 10-Q · filed 2026-05-07 | |||||
| 2025-09-30 | -$2.10M 10-Q · filed 2025-11-06 | -$1.50M derived: sum of 2 quarters · filed 2026-08-06 | $7.20M 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $600.00K 10-Q · filed 2026-08-06 | $9.30M 10-Q · filed 2026-08-06 | ||||
| 2025-03-31 | $8.70M 10-Q · filed 2026-05-07 | |||||
| 2024-09-30 | $900.00K 10-Q · filed 2025-11-06 | $4.30M 10-Q · filed 2024-11-07 | $9.30M derived: sum of 2 quarters · filed 2025-11-06 | $14.30M 10-Q · filed 2025-11-06 | $17.70M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $8.40M 10-Q · filed 2025-08-07 | $13.40M 10-Q · filed 2025-08-07 | ||||
| 2024-03-31 | $5.00M 10-Q · filed 2025-05-08 | |||||
| 2023-09-30 | $14.60M 10-Q · filed 2024-11-07 | $21.30M derived: sum of 2 quarters · filed 2024-11-07 | $29.00M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $6.70M 10-Q · filed 2024-08-08 | $14.40M 10-Q · filed 2024-08-08 | ||||
| 2023-03-31 | $7.70M 10-Q · filed 2024-05-09 | |||||
| 2022-12-31 | $84.70M 10-K · filed 2023-02-27 | |||||
| 2022-06-30 | $27.00M 10-Q · filed 2023-08-07 | $40.10M 10-Q · filed 2023-08-07 | ||||
| 2022-03-31 | $13.10M 10-Q · filed 2023-05-08 | |||||
| 2021-12-31 | $26.60M 10-K · filed 2023-02-27 | |||||
| 2020-12-31 | $300.00K 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |